VCYT Q4 2024 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$119M+20.8% YoY

Gross Profit

$79M66.4% margin

Operating Income

$4M3.5% margin

Net Income

$5M4.3% margin

EPS (Diluted)

$0.06

QoQ Revenue Growth

+2.4%

Cash Flow

Operating Cash Flow

$25M

Free Cash Flow

$20M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$124M

Stockholders' Equity

$1.2B

Cash & Equivalents

$239M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$119M	$98M	+20.8%
Gross Profit	$79M	$69M	+14.4%
Operating Income	$4M	-$36M	+111.8%
Net Income	$5M	-$28M	+118.1%

Revenue Segments

Testing

$219M94%

Biopharmaceutical And Other

$7M3%

Product

$7M3%

Geographic Segments

UNITED STATES

$424M95%

Non-US

$22M5%